SUMMARY -Th is case report presents a patient diagnosed with Tolosa-Hunt syndrome (THS) after an extensive neuro-diagnostic and neuroimaging evaluation. Diagnostic work-up included thorough physical and neurological examination, complete laboratory serum assessments, neuroendocrine and immunohistochemistry analysis, cerebrospinal fl uid analysis, neurophysiology assessment, ophthalmologist examination and neuroimaging. Th e most important diagnostic tool in deriving the diagnosis of THS was neuroimaging evaluation that included baseline and follow-up cranial contrast enhanced magnetic resonance imaging (MRI). Baseline cranial contrast enhanced MRI detected a nonspecifi c infl ammatory granulomatous lesion in the right cavernous sinus extending basally towards the right trigeminal cave (Meckel's cave) and anteriorly towards the apex of the right orbit. Systemic intravenous high-dose corticosteroid therapy was administered for 3 consecutive days and then tapered down to lower oral steroid doses. Following therapy, the patient experienced complete regression of symptoms. Follow-up cranial contrast enhanced MRI showed signifi cant regression of infl ammatory lesion in the area of right cavernous sinus, thus verifying the effi cacy of the treatment applied. Th is paper shows that an extensive diagnostic schedule for THS must be conducted prior to therapeutic treatment, for the possibility of alternative diagnosis. Patients suspected of having THS require careful evaluation, appropriate treatment, and follow-up.
Introduction
Tolosa-Hunt syndrome (THS) is a painful, usually unilateral ophthalmoparesis or ophthalmoplegia caused by nonspecifi c infl ammation (granulomatous or nongranulomatous) of the cavernous sinus or superior orbital fi ssure. Constant or episodic severe retro-orbital or periorbital pain is the initial feature of THS that usually resolves spontaneously but tends to relapse and remit. Double vision (diplopia) related to ophthalmoparesis or disordered eye movement occurs when cranial oculomotor (III), trochlear (IV), and abducens (VI) nerves are damaged by granulomatous infl ammation. Evidence of incomplete third nerve palsy with or without pupillary sparing may be present. Ptosis may be observed due to oculomotor palsy 1 . Th e etiology of THS remains unknown, although it might be commonly related to trauma, neoplasm, aneurysm, and infl ammation. It is known that THS responds well to systemic corticosteroid therapy, due to relapsing and remitting course. THS is rare during the fi rst 2 decades of life and afterwards it appears to have an even distribution. According to the International Headache Society 2013 classifi cation, THS is described as unilateral orbital pain associated with paresis of one or more of the third, fourth and/or fi fth cranial nerves caused by granulomatous infl ammation in the cavernous sinus, superior orbital fi ssure or orbit. Diagnostic criteria for the diagnosis of 13.7 THS, defi ned by the 3 rd edition of the International Classifi cation of Head-ache Disorders (ICHD-3), include: A. Unilateral headache fulfi lling criterion C; B. Both of the following: 1) granulomatous infl ammation of the cavernous sinus, superior orbital fi ssure or orbit, demonstrated by MRI or biopsy; 2) paresis of one or more of the ipsilateral third, fourth and/or fi fth cranial nerves; C. Evidence of causation demonstrated by both of the following: 1) headache has preceded paresis of the third, fourth and/or sixth nerves by ≤2 weeks, or developed with it; 2) headache is localized around the ipsilateral brow and eye; and D. Not better accounted for by another ICHD-3 diagnosis 2 . Pupillary dysfunction is related to injury of sympathetic fi bers in the cavernous portion of internal carotid artery (ICA) or parasympathetic fi bers that surround the oculomotor nerve. Infl ammatory involvement of the sympathetic nerves passing through the interior of the cavernous sinus may produce Horner syndrome with miosis. Th e combination of unilateral oculomotor palsy and Horner syndrome increases the localization specifi city for the cavernous sinus. Some reported cases of 13.7 THS had additional involvement of the fi fth nerve (commonly the fi rst division) or optic, seventh or eighth nerves. Sympathetic innervation of the pupil is occasionally aff ected. Trigeminal nerve involvement of fi rst division (primarily V1) may cause paresthesia of the forehead. Evidence of trigeminal nerve involvement is suggested by loss of the ipsilateral corneal refl ex. Lid swelling is more likely to occur with orbital disease rather than infl ammation limited to the cavernous sinus. Also, mild proptosis and/or optic disc edema may be noted if the orbit is involved. Pathologic involvement beyond the cavernous sinus, superior orbital fi ssure, or apex of the orbit occurs rarely, and the disorder is part of a continuum with idiopathic orbital pseudotumor, with which it shares histopathology features. A single pathognomonic characteristic of THS does not exist, thus it is often considered as a diagnosis of exclusion. Many of the processes that are found within the differential diagnosis of THS include tumors, vasculitis, basal meningitis, sarcoidosis, diabetes mellitus, and ophthalmoplegic migraine.
Case Report
A 54-year-old man was admitted to the Neurology Department, Sestre milosrdnice University Hospital Centre, due to severe frontal headache and right-sided periorbital pain, with the right eyelid ptosis and paresis of the right oculomotor cranial nerve. At admission, the patient was complaining of the right-sided supraorbital pain that expanded into the infraorbital area. During history taking, the patient reported that he had previously been hospitalized twice due to frontal headache, double vision and right-sided eyelid ptosis at neurology and ophthalmology departments, several months before. Medical history data revealed that in spite of the broad neurological and diagnostic examination, diagnosis has not been derived. After being discharged from the hospital, the patient experienced partial spontaneous regression of symptoms, without any treatment applied. At the current admission, the patient denied having nausea, fever, or recent head trauma. Alternative medical history was unremarkable and tick bite was excluded. Th e patient declared as non-smoker but acknowledged the habit of occasional, socially acceptable drinking. Previously established therapy schedule included ibuprofen as needed, duloxetine daily, acetylsalicylic acid daily and ophthalmic formulation of tobramycin solution, twice a day. Th e patient denied possible allergy to medications. Physical and neurological examination performed at admission verifi ed upper right-sided eyelid ptosis, right-sided oculomotor cranial nerve palsy and partial rightsided abducens nerve palsy without nystagmus (Fig.  1) . Emergency cranial multi-slice computed tomography (MSCT) was reported normal, without any detectable pathological morphological substrate. Laboratory analysis included hematologic tests (complete blood count, serum chemistry, erythrocyte sedimentation rate, C-reactive protein), and the fi ndings were normal. During hospitalization, contrast enhanced magnetic resonance imaging (MRI) with diff erent sequences was performed. Post contrast T1 MRI weighted images detected diff use enhancement in the area of the right cavernous sinus, extending basally towards the trigeminal cave and anteriorly towards the apex of the right orbit, with right-sided temporal-basal dural sheath imbibition and along the clivus. Hypointense signals were detected in the area of the right cavernous sinus and Meckel's cave on short tau inversion recovery (STIR) and T2 MRI weighted images (Figs. 2, 3  and 4) . In diff erential diagnosis, lesions were suggesting a nonspecifi c infl ammatory reaction or granulomatous infl ammation or possible lymphoid proliferative disease.
Cranial 3D time-of-fl ight (TOF) magnetic resonance angiography (MRA) fi nding was normal without any detectable aneurysm, vascular malformation or signifi cant stenosis in the cavernous or vertebral-basilar area. Analysis of cerebrospinal fl uid (CSF) showed proper function of the blood-brain barrier and the existence of oligoclonal immunoglobulin G (IgG) bands, without intrathecal synthesis, suggesting a systemic immune response. Immunohistochemistry analysis of tumor markers (TPA, CEA, CA 19-9, CYFRA 21-1) and laboratory analysis of thyroid hormones showed normal values, but the analysis of circulating immune complexes in the serum showed elevated titers of immunoglobulin IgG and IgM. Th us, the patient was referred to hematologist who suggested further diagnostic evaluation for possible vasculitis existence. Neurophysiology examination included blink refl ex and evoked potential testing: visual evoked potential (VEP), brainstem auditory evoked response (BAER) and somatosensory evoked potentials (SSEP). Findings of the tests performed were all normal except for SSEP of the median nerve that showed bilateral somatosensory stimulus transfer dysfunction at the level of the thalamus and somatosensory cortex. Th e patient was referred to ophthalmology examination and visual fi eld analysis, which indicated narrowing of the right visual fi eld above that corresponding to the eyelid ptosis. Systemic intravenous corticosteroid therapy with 1 000 mg methylprednisolone was administered for 3 consecutive days, along with gastroprotective therapy and continuous monitoring of steroid-related adverse eff ects. Systemic intravenous corticosteroid therapy resulted in complete regression of symptoms and the patient was discharged from the hospital for home care. He was recommended to take oral corticosteroids daily, according to the following tapering-off scheme: methylprednisolone 80 mg for 10 days, then 64 mg for 14 days, followed by 32 mg for 14 days, then 16 mg for 14 days, and fi nally methylprednisolone 8 mg. At neurological follow-up examination performed 3 months later, the patient was still complaining of blurred vision on the right eye, subjectively. Neurological and ophthalmological examination was performed and was regarded normal. Follow-up contrast enhanced MRI of the brain was performed and showed signifi cant regression of the post-contrast signal intensity in the right cavernous sinus, previously extending basally towards the trigeminal cave and anteriorly towards the apex of the right orbit, with right-sided temporal-basal dural sheath imbibition and imbibitions along the clivus (Fig. 5) . Th e patient was suggested to continue with oral corticosteroid therapy and recommended 4 mg methylprednisolone daily, and has not experienced relapse ever since.
Discussion
Th is case report presents the patient diagnosed with THS after extensive neurodiagnostic and MRI evaluation, which was the most important diagnostic tool in deriving the diagnosis of THS. Follow-up contrast enhanced MRI of the brain, performed 3 months after corticosteroid therapy administration, revealed complete regression of the pathologic substrate, thus confi rming the effi cacy of corticosteroid treatment. Th e study based on data from THS studies published from 1999 to 2007 examined credibility of the ICHD criteria for THS diagnosis. Study results confi rmed that defi nitive diagnosis of THS should be based on brain MRI, which was positive in 92.1% of THS patients because regression of symptoms was confi rmed in only 2% of patients within 72 hours after corticosteroid therapy application. Data analysis of the possible infl ammatory process localization included not only the cavernous sinus, but also the orbit (THS plus syndrome or pseudotumor) 3 . Furthermore, MRI analysis showed residual signs of infl ammation after the symptoms had subsided, thus suggesting that infl ammation might be present up to several months after regression of symptoms. Depending on the infl ammatory infi ltrate location, patients might present with various nonspecifi c symptoms that include nerve compression in cavernous sinus, partial or complete ophthalmoplegia indicating superior orbital fi ssure involvement, or loss of vision indicating optic nerve involvement; isolated trochlear nerve paresis has also been described 4 
.
Alternative diagnosis also included an extracranial dural metastatic neoplasm lesion, imitating meningioma that required surgical removal procedure. Th e major limitation of MRI fi ndings in THS is their lack of specifi city. A study that examined 11 patients has reported pathologic MRI fi ndings in the cavernous sinus in nine patients. In six of these nine patients, the affected cavernous sinus was enlarged, and in fi ve of nine patients it had a convex lateral wall. Extension into the orbital apex was seen in eight patients. Yet, the signal characteristics (hypointense relative to fat and isointense with muscle on T1 weighted images; isointense with fat on T2 weighted scans) were also consistent with meningioma, lymphoma, and sarcoidosis. Extensive diagnostic evaluation is warranted to exclude alternative causes of painful ophthalmoplegia and to confi rm THS diagnosis 5 . Th erefore, diagnostic processing usually includes complete laboratory work-up, thyroid hormone analysis, brain MRI and MRA, lumbar puncture and CSF analysis, vasculitis assessment, an ophthalmologist and otolaryngologist examination, x-ray of the heart and lungs, abdomen ultrasound, and fi nally biopsy of the lesion previously verifi ed by brain MRI. Th e above is important for the successful treatment of THS and other diff erential diseases. In the literature, one can fi nd diff erent doses of corticosteroids applied for THS treatment because there are no specifi c guidelines for the THS therapeutic approach. During hospitalization, our patient had partially recovered spontaneously, but after systemic corticosteroid treatment, regression of symptoms was complete. We treated our patient with the intravenously applied corticosteroid therapy with 1 gram of methylprednisolone daily, applied for 3 consecutive days. Following systemic therapy, the patient was tapered down to lower doses of corticosteroids, applied orally. Some authors used lower doses of oral corticosteroids (60 mg or 125 mg), and had positive therapeutic response 6 . When corticosteroids are contraindicated or serious side eff ects are present, corticosteroid treatment should be discontinued. Patients on long-term corticosteroid use and persistent or recurrent symptoms could be treated with azathioprine, methotrexate or radiation therapy [7] [8] [9] . Literature data show that symptom regression and normalization of MRI fi ndings occur faster in patients treated with high-dose corticosteroids in comparison to low-dose corticosteroids, although the diff erence was not statistically signifi cant. Recurrence of symptoms was recorded in 44.2% of patients treated with low-dose corticosteroids, as opposed to 10% of patients treated with high-dose corticosteroids, sug-gesting the importance of patient follow-up 10 . Patient observation during therapy application, continuous follow-up and cranial MRI follow-up with the focus on the cavernous sinus and orbital apex is recommended in the evaluation of THS symptom regression and therapeutic effi cacy [11] [12] [13] [14] [15] .
Conclusion
Th e diagnosis of THS is often made after alternative disease processes have been excluded. Extensive diagnostic evaluation is warranted to exclude the possible causes of painful ophthalmoplegia. Diff erential diagnosis of THS includes parasellar syndrome causes (trauma), neoplasms (primary intracranial tumor, local or distant metastases), vascular causes (aneurysm, carotid dissection, carotid cavernous fi stula), infl ammation (orbital pseudotumor, giant cell arteritis, sarcoidosis), infectious etiology (fungi, mycobacteria, etc.) 12 or other (micro vascular infarcts, diabetes mellitus, recurrent painful ophthalmoplegic neuropathy). Additional causes of painful ophthalmoplegia include orbital disease, posterior fossa aneurysm and ophthalmoplegic migraine. Evidently, various disorders and disease processes are included in the diff erential diagnosis of THS, thus patients suspected of having THS require careful evaluation, appropriate treatment, and followup observation of therapy applied.
